IFN-α2, IFN-γ and IL-2 treatment leads to changes in CD8+ TIL phenotypes.

<p>Mice harboring subcutaneous B16.OVA tumors were treated intraperitoneally with 2x10⁶ CD8a⁺ enriched OT-I lymphocytes and injected intratumorally with either PBS or recombinant cytokine in PBS or left non-injected (n = 5). (a) Levels of tumor-infiltrating endogenous (non-OVA) CD8⁺ T-cells and (b) count of central memory (T_CM) and effector memory (T_EM) T-cells were assessed from tumors on day 14 post-transfer by flow cytometry. (c) Activation status of tumor-infiltrating CD8+ T-cells was evaluated on day 14 by expression of CD69 and IFN-γ following PMA/Ionomycin stimulation <i>ex vivo</i>. Data presented as mean ± SEM. *P ≤ 0.05 and **P≤ 0.01 by one-way ANOVA followed by Tukey’s post-hoc test.